TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27094910

Group type: EXPERIMENTAL
Intervention: Reproductive health education and tailored counseling sessions
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Usual prenatal care (PNC)
Number of subjects: 1044
Study: 24510841

Group type: EXPERIMENTAL
Intervention: 800 kcal lunch
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: 1,600 kcal lunch
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: 400 kcal lunch
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control group (no free lunch)
Number of subjects: 233
Study: 22948494

Group type: EXPERIMENTAL
Intervention: Bowel management system catheter
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Rectal/nasopharyngeal trumpet
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Internal fecal devices
Number of subjects: 59
Study: 20625082

Group type: EXPERIMENTAL
Intervention: IH with placebo medication
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham IH
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IH with losartan (type I angiotensin II receptor antagonist)
Number of subjects: 9
Study: 18346622

Group type: EXPERIMENTAL
Intervention: Reflexology treatment (40 min, once per week for six weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment (40 min, once per week for six weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reflexology treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study: 15981065

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation with polyethylene glycol (PEG group)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Normal meal preoperatively (normal meal preoperatively group)
Number of subjects: 250
Study: 12521651

Group type: EXPERIMENTAL
Intervention: Continuous group (168 days without a pill-free interval)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard group (6 cycles of 28 days)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Continuous group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 32
Study: 9661567

Group type: EXPERIMENTAL
Intervention: Clonidine (2 micrograms/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam (70 micrograms/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7634942

Group type: EXPERIMENTAL
Intervention: Extramucosal pyloroplasty
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no pyloroplasty)
Number of subjects: 107
Study: 2694742

Group type: EXPERIMENTAL
Intervention: Clindamycin (single preoperative dose)
Number of subjects: 166

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 166
Study: 786668

Group type: EXPERIMENTAL
Intervention: Intramuscular meperidine (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral meperidine (150 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of intramuscular dose (mg/kg)
Number of subjects: 0
Study: 31613994

Group type: EXPERIMENTAL
Intervention: Clearsonic ultrasonic tip
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reciproc R40 instrument
Number of subjects: 20
Study: 29779350

Group type: EXPERIMENTAL
Intervention: pd‐FⅨ (plasma derived coagulation Factor Ⅸ concentrate)
Number of subjects: 36
Study: 28579415

Group type: EXPERIMENTAL
Intervention: Elagolix alone (100 mg BID, 200 mg BID, 300 mg BID, 400 mg QD, 600 mg QD)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Elagolix with add-back therapy (200 mg BID plus continuous low-dose E2 0.5 mg/norethindrone acetate 0.1 mg or elagolix 300 mg BID plus E2 1 mg continuously and cyclical P 200 mg)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Overall adverse events (AEs)
Number of subjects: 271
Study: 25707611

Group type: EXPERIMENTAL
Intervention: Blosozumab 270 mg every 2 weeks (Q2W)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Blosozumab 180 mg every 2 weeks (Q2W)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Blosozumab
Number of subjects: 120
Study: 23820652

Group type: EXPERIMENTAL
Intervention: Periprostatic nerve blockade in addition to intrarectal lidocaine gel
Number of subjects: 473

Group type: COMPARATOR
Intervention: Intrarectal lidocaine gel
Number of subjects: 473
Study: 21131286

Group type: EXPERIMENTAL
Intervention: Provider training and materials to improve risk factor reporting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control facilities (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-post difference for intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-post difference for control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AIDS cases from intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: AIDS cases from control
Number of subjects: 0
Study: 19032723

Group type: EXPERIMENTAL
Intervention: Ibudilast 30 mg single administration followed by 30 mg b.i.d. for 14 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16452912

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg daily)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 14604716

Group type: EXPERIMENTAL
Intervention: Applanation ultrasound (US)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Experienced operators
Number of subjects: 377
Study: 11281167

Group type: EXPERIMENTAL
Intervention: Oleic acid emulsion (1.6 ml)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oleic acid emulsion (3.2 ml)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control emulsion (0 ml oleic acid)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oleic acid treatment
Number of subjects: 45
Study: 9012637

Group type: EXPERIMENTAL
Intervention: Factor VII coagulant activity (VIIc)
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: Changes in VIIc
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: Factor VII antigen (VIIag)
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: Partial correlation coefficients after adjustment for sex and race
Number of subjects: 1514
Study: 8140906

Group type: EXPERIMENTAL
Intervention: Mianserin (daily dose 20-60 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 22
Study: 2849539

Group type: EXPERIMENTAL
Intervention: NaHCO3 treatment (2.9 mmol of NaHCO3.kg‐1 body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo treatment (17 mmol of NaCl)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No-drink treatment
Number of subjects: 10
Study: 2062514

Group type: EXPERIMENTAL
Intervention: Nonsimultaneous stereoscopic fluorescein angiography
Number of subjects: 0
Study: 560645

Group type: EXPERIMENTAL
Intervention: 200 mg tyramine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 31580100

Group type: EXPERIMENTAL
Intervention: Experimental training condition (discriminating between faces that differed in feature size or spacing across 10 levels of difficulty)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Active control training condition (playing the standard version of Guess Who)
Number of subjects: 81
Study: 30178577

Group type: EXPERIMENTAL
Intervention: 100 mg oral aspirin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27846743

Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor, 5 mg od)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Candesartan (AT1R antagonist, 8 mg od)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 30
Study: 24520880

Group type: EXPERIMENTAL
Intervention: (99m) Tc‐DTPA aerosol scintigraphy in nonsmoking COPD patients
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 84
Study: 27366374

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard technique)
Number of subjects: 0
Study: 20884019

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: LVAD implantation
Number of subjects: 47
Study: 19365150

Group type: EXPERIMENTAL
Intervention: ABIO-08/01 (10 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ABIO-08/01 (20 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ABIO-08/01 (40 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17498886

Group type: EXPERIMENTAL
Intervention: Goserelin and flutamide for 2 months before and during radiation therapy (RT) +/− 24 months of goserelin (long-term androgen deprivation plus radiation [LTAD-RT])
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Goserelin and flutamide for 2 months before and during RT +/− 24 months of goserelin (LTAD-RT)
Number of subjects: 197
Study: 15161117

Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg once daily
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: rofecoxib 50 mg once daily
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: naproxen 500 mg twice daily
Number of subjects: 183

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 183
Study: 11261891

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional dose chemotherapy
Number of subjects: 0
Study: 9540364

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7905523

Group type: EXPERIMENTAL
Intervention: Combination therapy with N-butyl-deoxynojirimycin (SC-48334) and zidovudine (1000 mg every 8 h and 100 mg every 8 h, respectively)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Zidovudine and placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Combination therapy with N-butyl-deoxynojirimycin (SC-48334) and zidovudine
Number of subjects: 118
Study: 2594133

Group type: EXPERIMENTAL
Intervention: Intraventricular injection of morphine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural injection of morphine
Number of subjects: 50
Study: 31670776

Group type: EXPERIMENTAL
Intervention: Continuous transversus abdominis plane block
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham block (subcutaneous)
Number of subjects: 90
Study: 30951210

Group type: EXPERIMENTAL
Intervention: Achieving at least a 1-level reduction in WHO risk drinking levels by the end of treatment
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Achieving at least a 2-level reduction in WHO risk drinking levels by the end of treatment
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: WHO risk level reductions
Number of subjects: 1226
Study: 29279933

Group type: EXPERIMENTAL
Intervention: Cefazolin (1000 mg intravenous preoperative dose)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Saline (0.9% sodium chloride intravenous preoperative dose)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Cefazolin vs Saline
Number of subjects: 500
Study: 25925742

Group type: EXPERIMENTAL
Intervention: Gold standard programme for alcohol cessation intervention, including structured patient education, weekly intervention meetings, thiamine and B-vitamins, alcohol withdrawal prophylaxis, and disulfiram for abstinence support.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 24393553

Group type: EXPERIMENTAL
Intervention: 5 mg linagliptin once daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2.5 mg linagliptin
Number of subjects: 36
Study: 20680276

Group type: EXPERIMENTAL
Intervention: Surgical treatment (closed reduction followed by fragment excision)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conservative treatment (closed reduction)
Number of subjects: 16
Study: 19690484

Group type: EXPERIMENTAL
Intervention: 3-cm side limb
Number of subjects: 44

Group type: COMPARATOR
Intervention: 6-cm side limb
Number of subjects: 44
Study: 16374142

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day after 12 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lipid-lowering diet (control period)
Number of subjects: 36
Study: 15185228

Group type: EXPERIMENTAL
Intervention: Complete resection (CR)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Less than complete resection (MR or PR)
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Minimal residual (MR)
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Partial resection (PR)
Number of subjects: 539
Study: 10874282

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 30
Study: 9184014

Group type: EXPERIMENTAL
Intervention: Urban sample (Madrid)
Number of subjects: 1259

Group type: EXPERIMENTAL
Intervention: Rural sample (Arévalo, Avila)
Number of subjects: 1259
Study: 1410747

Group type: EXPERIMENTAL
Intervention: Fentanyl 3‐5 micrograms/kg, 5 minutes before implantation of craniostate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Subcutaneous infiltration of mepivacaine 2% at craniostate fixation points
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Blockade of frontal and occipital nerves
Number of subjects: 34
Study: 2866291

Group type: EXPERIMENTAL
Intervention: Saline infusion (2 litres of 0.9% saline over 1 hour)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low sodium diet (10 mmol/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal sodium intake (150 mmol/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High salt intake (350 mmol/day)
Number of subjects: 0
Study: 30893216

Group type: EXPERIMENTAL
Intervention: Short InterTAN device (180‐200 mm)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Long InterTAN device (260‐460 mm)
Number of subjects: 108
Study: 29172800

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire (Group A)
Number of subjects: 842

Group type: COMPARATOR
Intervention: GP-administered questionnaire (Group B)
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 842
Study: 28304291

Group type: EXPERIMENTAL
Intervention: Insulin Resistance (top HOMA-IR quartile)
Number of subjects: 489
Study: 25899029

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion (0.15 mmol/kg body weight/h)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Control (no sodium bicarbonate infusion)
Number of subjects: 342
Study: 23743672

Group type: EXPERIMENTAL
Intervention: Supine group (SG); n=54
Number of subjects: 100

Group type: COMPARATOR
Intervention: Turning group (TG); n=46
Number of subjects: 100
Study: 20184225

Group type: EXPERIMENTAL
Intervention: Triflusal oral solution (600 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Triflusal capsules (300 mg x 2)
Number of subjects: 24
Study: 19133017

Group type: EXPERIMENTAL
Intervention: HD with PES
Number of subjects: 8

Group type: COMPARATOR
Intervention: HDF with POX
Number of subjects: 8

Group type: COMPARATOR
Intervention: HDF with PSU
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 8
Study: 15893540

Group type: EXPERIMENTAL
Intervention: Marimastat (5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12849799

Group type: EXPERIMENTAL
Intervention: Contraceptive patch (group 1 and group 2)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Oral contraceptives (OCs)
Number of subjects: 124
Study: 10593469

Group type: EXPERIMENTAL
Intervention: Lateral infraclavicular approach (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Axillary approach (n=20)
Number of subjects: 40
Study: 8941827

Group type: EXPERIMENTAL
Intervention: Chelon‐Silver
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ketac‐Silver
Number of subjects: 2

Group type: COMPARATOR
Intervention: Dispersalloy
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: All groups (Chelon‐Silver, Ketac‐Silver, Dispersalloy)
Number of subjects: 2
Study: 1768561

Group type: EXPERIMENTAL
Intervention: Levodopa (125 mg, three oral doses at 2-hour intervals)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (two doses)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Co-administration of soluble paracetamol with levodopa
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Co-administration of radiolabelled DTPA with levodopa
Number of subjects: 8
Study: 6456699

Group type: EXPERIMENTAL
Intervention: Topically applied clindamycin hydrochloride and clindamycin phosphate (2% concentration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroalcoholic products (control)
Number of subjects: 0
Study: 30376364

Group type: EXPERIMENTAL
Intervention: Kawashima Brain Training (KBT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Super Mario Bros (SMB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No-training no-contact control group
Number of subjects: 36
Study: 28675824

Group type: EXPERIMENTAL
Intervention: Bag-shaped swaddling clothing (n=27)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional swaddling (n=12)
Number of subjects: 39
Study: 25455721

Group type: EXPERIMENTAL
Intervention: 100,000 units oral vitamin D3 every 2 months for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 50
Study: 22773397

Group type: EXPERIMENTAL
Intervention: 1 g cefazolin systemically 10 minutes before tourniquet inflation
Number of subjects: 22

Group type: COMPARATOR
Intervention: 1 g cefazolin intraosseously in 200 mL of normal saline after tourniquet inflation
Number of subjects: 22
Study: 22093786

Group type: EXPERIMENTAL
Intervention: Docetaxel plus THP & CTX
Number of subjects: 97

Group type: COMPARATOR
Intervention: Paclitaxel plus THP & CTX
Number of subjects: 97
Study: 19418497

Group type: EXPERIMENTAL
Intervention: EPCA‐2.19 assay
Number of subjects: 328
Study: 16581485

Group type: EXPERIMENTAL
Intervention: SLE patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SLE patients with PH
Number of subjects: 40
Study: 12875066

Group type: EXPERIMENTAL
Intervention: Anti-epilepsy capsules
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Luminal (control)
Number of subjects: 1090
Study: 10868558

Group type: EXPERIMENTAL
Intervention: Loratadine syrup (5 mg, 1 mg/mL)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 1491863

Group type: EXPERIMENTAL
Intervention: Odorized 35-40% nitrous oxide/oxygen gas mixture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Odorized placebo gas mixture
Number of subjects: 0
Study: 3080865

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (IV)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intragastric nutrition (IG)
Number of subjects: 20
Study: 29114936

Group type: EXPERIMENTAL
Intervention: Simple training comprising four basic, single‐molecule substances
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Complex training involving four odor mixtures
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Odor‐altering training in which patients changed sets of mixtures every 2 months
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Overall TDI score increase
Number of subjects: 108
Study: 27068399

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (300/100 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (800/100 mg)
Number of subjects: 120
Study: 23913807

Group type: EXPERIMENTAL
Intervention: HF/LED (high-fat low-energy density diet, 1.05 kcal/g)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HF/HED (high-fat high-energy density diet, 1.60 kcal/g)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HC/LED (high-carbohydrate low-energy density diet, 1.05 kcal/g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: HF/HED
Number of subjects: 20

Group type: COMPARATOR
Intervention: HF/LED
Number of subjects: 20
Study: 22435779

Group type: EXPERIMENTAL
Intervention: High-intensity intermittent exercise (5×30 s maximal sprints)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (rest)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Walking (30 min brisk walking)
Number of subjects: 9
Study: 20105163

Group type: EXPERIMENTAL
Intervention: GR1 (1‐hour, 50‐g glucose screen +/‐ 3‐hour, 100‐g OGTT)
Number of subjects: 1594

Group type: EXPERIMENTAL
Intervention: GR2 (50‐g GS +/‐ 2‐hour, 75‐g OGTT)
Number of subjects: 1594

Group type: COMPARATOR
Intervention: GR3 (2‐hour, 75‐g OGTT)
Number of subjects: 1594
Study: 17297614

Group type: EXPERIMENTAL
Intervention: LED phototherapy (LPT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional phototherapy (CPT)
Number of subjects: 31
Study: 15639634

Group type: EXPERIMENTAL
Intervention: Turkish version of WOMAC osteoarthritis index
Number of subjects: 72
Study: 12574898

Group type: EXPERIMENTAL
Intervention: Colchicine (1.5 mg/day) for 1 month
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 111
Study: 10723222

Group type: EXPERIMENTAL
Intervention: Serum IgG level against A60 mycobacterial antigen measured by ELISA
Number of subjects: 76

Group type: COMPARATOR
Intervention: Healthy controls (23 total)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sarcoidosis patients (20 total)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Lung cancer patients (17 total)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Patients with mycobacterial infections other than tuberculosis (8 total)
Number of subjects: 76
Study: 8856618

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Diclofenac sodium (DS)
Number of subjects: 146
Study: 1731034

Group type: EXPERIMENTAL
Intervention: Daily maintenance sodium (3 to 4 mEq of sodium per kilogram per day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Salt restriction (no sodium supplement other than with treatments such as transfusion)
Number of subjects: 17
Study: 6376301

Group type: EXPERIMENTAL
Intervention: Tetrachlorodecaoxide (TCDO) in a water solution containing glycerin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Physiological sodium chloride (control)
Number of subjects: 38
Study: 31669446

Group type: EXPERIMENTAL
Intervention: Parenting for Lifelong Health for Young Children intervention (5 vs. 10 sessions, basic vs. enhanced package, on-demand vs. structured supervision)
Number of subjects: 864

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 864